Advertisement

Cisplatin

  • Ines Mader
  • Patrizia E. Fürst-Weger
  • Robert M. Mader
  • Elisabeth I. Semenitz
  • Robert Terkola
  • Sabine M. Wassertheurer

Keywords

Natl Cancer Inst Silver Sulfadiazine Topical Cool Extravasation Injury Cancer Chemotherapeutic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. [1]
    Lewis KP, Medina WD: Cellulitis and fibrosis due to cisdiamminedichloroplatinum (II) (platinol) infiltration. Cancer Treat Rep 64: 1162–1163, 1980.PubMedGoogle Scholar
  2. [2]
    Leyden M, Sullivan J: Full-thickness skin necrosis due to inadvertent interstitial infusion of cisplatin. Cancer Treat Rep 67: 199, 1983.PubMedGoogle Scholar
  3. [3]
    Algarra SM, Dy C, Bilbao I, et al: Cutaneous necrosis after intra-arterial treatment with cisplatin. Cancer Treat Rep 70: 687–688, 1986.Google Scholar
  4. [4]
    Bairey O, Bishara J, Stahl B, et al: Severe tissue necrosis after cisplatin extravasation at low concentration: possible “immediate recall phenomenon’: J Natl Cancer Inst 89: 1233–1234, 1997.PubMedGoogle Scholar
  5. [5]
    Howell SB, Taetle R: Effect of sodium thiosulfate on cisdichlorodiammineplatinum (II) toxicity and antitumor activity in L1210 leukemia. Cancer Treat Rep 64: 611–616, 1980.PubMedGoogle Scholar
  6. [6]
    Bertelli G, Gozza A, Forno GB, et al: Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13: 2851–2855, 1995.PubMedGoogle Scholar
  7. [7]
    Bertelli G, Dini D, Forno G, et al: Dimethylsulphoxide and cooling after extravasation of antitumour agents. Lancet 341: 1098–1099, 1993.PubMedCrossRefGoogle Scholar
  8. [8]
    Fields S, Koeller J, Topper RL, et al: Local soft tissue toxicity following cisplatin extravasation. J Natl Cancer Inst 82: 1649–1650, 1990.PubMedCrossRefGoogle Scholar

Secondary literature

  1. [9]
    Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.PubMedCrossRefGoogle Scholar
  2. [10]
    Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.Google Scholar
  3. [11]
    Root T: Chemotherapeutic agents: cisplatin. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 203–207, 1997.Google Scholar
  4. [12]
    Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.PubMedCrossRefGoogle Scholar
  5. [13]
    Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.Google Scholar
  6. [14]
    Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.PubMedGoogle Scholar
  7. [15]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.Google Scholar
  8. [16]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Cisplatin: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: 61, 1997.Google Scholar
  9. [17]
    Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton and Lange, 2nd edition: 109–118, 1994.Google Scholar
  10. [18]
    Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.PubMedCrossRefGoogle Scholar
  11. [19]
    Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxicdrug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.PubMedGoogle Scholar
  12. [20]
    Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.Google Scholar
  13. [21]
    Barth J: Paravasate und deren Behandlung. In: Barth J (ed) ZytostatikaHerstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.Google Scholar

Further reading

  1. Buchanan GR, Buchsbaum HJ, O’Banion K, et al: Extravasation of dacti-nomycin, vincristine, and cisplatin: studies in an animal model. Med Pediatr Oncol 13: 375–380, 1985.PubMedCrossRefGoogle Scholar
  2. Dorr RT, Alberts DS, Soble M: Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone. Cancer Chemother Pharmacol 16: 91–94, 1986.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Ines Mader
    • 1
  • Patrizia E. Fürst-Weger
    • 2
  • Robert M. Mader
    • 3
  • Elisabeth I. Semenitz
    • 4
  • Robert Terkola
    • 5
  • Sabine M. Wassertheurer
    • 6
  1. 1.Austrian Breast and Colorectal Cancer Study GroupViennaAustria
  2. 2.SMZ FloridsdorfKrankenhaus und GeriatriezentrumViennaAustria
  3. 3.Clinical Division of Oncology, Department of Medicine IUniversity HospitalViennaAustria
  4. 4.AnstaltsapothekeLandeskrankenhaus — Universitätskliniken InnsbruckAustria
  5. 5.Kaiser-Franz-Josef HospitalViennaAustria
  6. 6.Apotheke LKH-Univ.-Klinikum GrazAustria

Personalised recommendations